Identification of a VHL gene mutation in a Chinese family with Von Hippel‑Lindau syndrome

He,Zhengwen; Xia,Lu; Deng,Zhiyong; Lian,Aojie; Hu,Zhengmao; Li,Bin

doi:10.3892/mmr.2018.8974

Identification of a VHL gene mutation in a Chinese family with Von Hippel‑Lindau syndrome

Authors:
- Zhengwen He
- Lu Xia
- Zhiyong Deng
- Aojie Lian
- Zhengmao Hu
- Bin Li
View Affiliations

Affiliations: Department of Neurosurgery, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya, School of Medicine, Central South University, Changsha, Hunan 410008, P.R. China, Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan 410008, P.R. China, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 4, 2018 https://doi.org/10.3892/mmr.2018.8974
Pages: 435-440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Von Hippel‑Lindau (VHL) syndrome is an autosomal dominant neoplastic disorder. The VHL tumor suppressor (VHL) gene has previously been identified to represent the causative gene of VHL. Previous studies have demonstrated that >506 different mutations in VHL are associated with VHL syndrome. The aim of the present study was to determine the VHL gene mutation present in a VHL syndrome pedigree and to investigate the pathogenesis of the mutant protein. Briefly, a family suffering from VHL syndrome in a Chinese Han population was recruited, and a missense mutation (c.345 C>A: p.H115Q) was revealed to be present within the VHL gene in the proband. Furthermore, Sanger sequencing revealed two carriers of the mutation within the family. The results of the present study also demonstrated a mutation in VHL associated with the VHL syndrome phenotype, which may be of future therapeutic benefit for the diagnosis of VHL syndrome. These results may also be relevant to further studies aiming to investigate the molecular pathogenesis of VHL syndrome.

View Figures

View References

1	Maher ER, Neumann HP and Richard S: von Hippel-Lindau disease: A clinical and scientific review. Eur J Hum Genet. 19:617–623. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hes FJ, Höppener JW, Luijt RB and Lips CJ: Von hippel-lindau disease. Hered Cancer Clin Pract. 3:171–178. 2005. View Article : Google Scholar : PubMed/NCBI
3	Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat. 5:66–75. 1995. View Article : Google Scholar : PubMed/NCBI
4	Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M and Kaelin WG Jr: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 10:1019–1027. 2001. View Article : Google Scholar : PubMed/NCBI
5	Neumann HP and Wiestler OD: Clustering of features of von Hippel-Lindau syndrome: Evidence for a complex genetic locus. Lancet. 337:1052–1054. 1991. View Article : Google Scholar : PubMed/NCBI
6	Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 260:1317–1320. 1993. View Article : Google Scholar : PubMed/NCBI
7	Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J, et al: Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci USA. 88:2864–2868. 1991. View Article : Google Scholar : PubMed/NCBI
8	Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT and Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 77:1151–1163. 1990. View Article : Google Scholar : PubMed/NCBI
9	Iliopoulos O, Ohh M and Kaelin WG Jr: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA. 95:11661–11666. 1998. View Article : Google Scholar : PubMed/NCBI
10	Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr and Pavletich NP: Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science. 296:1886–1889. 2002. View Article : Google Scholar : PubMed/NCBI
11	Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin WG Jr: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
12	Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yu F, White SB, Zhao Q and Lee FS: HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 98:9630–9635. 2001. View Article : Google Scholar : PubMed/NCBI
14	Sun W, Kato H, Kitajima S, Lee KL, Gradin K, Okamoto T and Poelllinger L: Interaction between von Hippel-Lindau protein and fatty acid synthase modulates hypoxia target gene expression. Sci Rep. 7:71902017. View Article : Google Scholar : PubMed/NCBI
15	Stephen H: Harrison's Neurology in Clinical Medicine. 2nd editon. McGraw-Hill; London: 2010
16	Rosai J: Rosai and Ackerman's surgical pathology-2 Volume Set. 10th Edition. Mosby: 2011, View Article : Google Scholar
17	Sambrook J and Russell D: Molecular cloning: A laboratory manual (Third Edition). Cold Spring Harb Lab. 2016.
18	Enriquez ML, Lal P, Ziober A, Wang L, Tomaszewski JE and Bing Z: The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl Immunohistochem Mol Morphol. 20:141–145. 2012. View Article : Google Scholar : PubMed/NCBI
19	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
20	Barry RE and Krek W: The von Hippel-Lindau tumour suppressor: A multi-faceted inhibitor of tumourigenesis. Trends Mol Med. 10:466–472. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kleymenova E, Everitt JI, Pluta L, Portis M, Gnarra JR and Walker CL: Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis. 25:309–315. 2004. View Article : Google Scholar : PubMed/NCBI
22	Jia D, Tang B, Shi Y, Wang J, Sun Z, Chen Z, Zhang L, Xia K and Jiang H: A deletion mutation of the VHL gene associated with a patient with sporadic von Hippel-Lindau disease. J Clin Neurosci. 20:842–847. 2013. View Article : Google Scholar : PubMed/NCBI
23	Yang Z, Yang Z, Xiong L, Huang S, Liu J, Yang L and Miao X: Expression of VHL and HIF-1α and their clinicopathologic significance in benign and malignant lesions of the gallbladder. Appl Immunohistochem Mol Morphol. 19:534–539. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kibel A, Iliopoulos O, DeCaprio JA and Kaelin WG Jr: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 269:1444–1446. 1995. View Article : Google Scholar : PubMed/NCBI
25	Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S and Kaelin WG Jr: Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 27:5381–5392. 2007. View Article : Google Scholar : PubMed/NCBI
26	Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:820–823. 1971. View Article : Google Scholar : PubMed/NCBI
27	Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD and Linehan WM: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA. 94:9102–9107. 1997. View Article : Google Scholar : PubMed/NCBI
28	Ma W, Tessarollo L, Hong SB, Baba M, Southon E, Back TC, Spence S, Lobe CG, Sharma N, Maher GW, et al: Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 63:5320–5328. 2003.PubMed/NCBI
29	Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H and Rechsteiner M: Detecting circulating tumor DNA in renal cancer: An open challenge. Exp Mol Pathol. 102:255–261. 2017. View Article : Google Scholar : PubMed/NCBI